Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 42

  • 13

  • 12

  • 6

  • 6

  • 4

  • 3

  • 2

  • 2

  • 2

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

Modulation of regulatory T cells in the bladder tumor environment by anti-PD-L1 immunotherapy

Funder: Bladder Cancer Advocacy Network

Funding period
USD 50 K
Funding amount
Abstract
Immunotherapies, specifically checkpoint inhibitors blocking PD ligand-1 (PD-L1) and its inhibitory receptor PD-1, lead to durable responses in a minority of patients with platinum-refractory and platinum-naïve bladder transitional cell carcinoma (TCC), and improved survival in the platinum-refractory setting. However, the features that predict responses, and the immune populations in TCC that are responsible for benefit with anti-PD-1/PD-L1, remain obscure. This proposal addresses the novel hypothesis that anti-PD-L1 modulates the activity of regulatory T cells (Tregs), which we and others have described in TCC, and addresses the following Specific Aims: 1. Does anti-PD-L1 therapy reduce the abundance of Tregs, including in specific spatial microenvironments associated with TCC tumors? 2. Does anti-PD-L1 therapy change the antigenic repertoire of Tregs in TCC? These Aims will be addressed using samples, specifically pre-treatment biopsies and immunotherapy-treated cystectomy specimens, from patients with localized TCC treated with neoadjuvant atezolizumab (anti-PD-L1) before cystectomy as part of an ongoing clinical trial, as well as patients from a companion cohort of non-immunotherapy-treated TCC patients (standard of care). Aim 1 addresses effects of anti-PD-L1 on Treg number and distribution via flow cytometric and immunohistochemical comparison of atezolizumab-treated cystectomies and either paired pre-treatment biopsies or standard of care cystectomies. Aim 2 uses T cell receptor (TCR) sequencing of Tregs from atezolizumab-treated and standard of care cystectomies as well as paired pre-treatment biopsies, to understand how anti-PD-L1 modulates Treg TCR repertoire diversity as well as the frequency of specific Treg clonotypes. This will reveal novel roles for Tregs in responsiveness to anti-PD-L1 in TCC, leading to avenues for therapeutic targeting of Tregs or enhancement of immune responses to specific tumor antigens that are suppressed by Tregs.

 
106
Projects
USD 46.5 M
Aggregated funding amount
USD 674 K
Average funding amount
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Transdifferentiation of fibroblasts to urothelial progenitors for definitive urothelial replacement therapy in non-muscle invasive bladder cancer

Bladder Cancer Advocacy Network to Philip A Beachy, Kris Butalid Prado

USD 300,000
2019 - 2021
Project list item
Targeting FGF in Bladder cancer after Neoadjuvant Immunotherapy and Surgery

American Association For Cancer Research to Joshua James Meeks

USD 25,000
2019 - 2020
Project list item
[Chemoradiotherapy with MMC and UFT for muscle-invasive bladder cancer in elderly patients] - Original in Japanese

Japan Society for the Promotion of Science to Hisanori ARIGA, 光洋 菊池

USD 35,916
2019 - 2024
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 1,313,632
2019 - 2024
Project list item
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

National Cancer Institute to HIKMAT AL-AHMADIE

USD 821,670
2019 - 2024
Project list item
Clonal evolution and molecular stratification of urothelial carcinoma in situ of the urinary bladder

German Research Foundation to Nadine Gaisa, Stefan Garczyk

 
2019 -
Project list item
Ultrasound-based diagnostic and monitoring of bladder cancer treatment with drug released from nanoparticles

National Cancer Institute to JOE ASSOULINE, YI LUO

USD 350,240
2018 - 2020
Project list item
Novel recombinant BCG for immunotherapy of bladder cancer

National Cancer Institute to BORIS SHOR

USD 290,014
2018 - 2020
Project list item
SPORE in Bladder Cancer

National Cancer Institute to DEAN F. BAJORIN, TIMOTHY AN-THY CHAN, MICHAEL STEPHEN GLICKMAN, IRINA OSTROVNAYA, HIKMAT AL-AHMADIE, DAVID B SOLIT

USD 4,438,686
2018 - 2023
Project list item
Deciphering the neoantigen landscape in bladder cancer patients

Swiss National Science Foundation to Laurent Derré, Sylvain Nguyen, Alexandre Harari

USD 642,703
2018 - 2022
Project list item
Development of Classifiers for Novel Bladder Cancer Subtypes

Congressionally Directed Medical Research Programs to Woonyoung Choi

USD 856,134
2017 - 2018
Project list item
Development of Classifiers for Novel Bladder Cancer Subtypes

Congressionally Directed Medical Research Programs to Seungchan Kim

USD 706,947
2017 - 2018
Project list item
The Mechanism of Antitumor Immunity Induced by BCG Therapy for Bladder Cancer

Congressionally Directed Medical Research Programs to Anthony C Antonelli

USD 188,994
2017 - 2018
Project list item
Immunologic and Microbial Correlates and Mechanisms of Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

Congressionally Directed Medical Research Programs to Philip Abbosh

USD 658,800
2017 - 2018
Project list item
INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCER

National Cancer Institute to ROSA MARIA DIAZ, LUKKANA SUKSANPAISAN, BRADLEY C. LEIBOVICH

USD 1,990,950
2017 - 2020
Project list item
Defining the Immune Response to Chemotherapy and Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer

Bladder Cancer Advocacy Network to Tracy L Rose, William Youngkwan Kim, Matthew Milowsky, Benjamin Vincent

USD 50,000
2017 - 2018
Project list item
Development of personalized surgical algorithms for muscle-invasive bladder cancer patients

National Cancer Institute to PHILIP ABBOSH

USD 437,828
2017 - 2019
load more...